New drug duo tested to fight Tough-to-Treat lung cancer
NCT ID NCT03184571
Summary
This study tested whether adding a new drug called bemcentinib (BGB324) to an existing immunotherapy (pembrolizumab) could help control advanced lung cancer that had worsened after prior treatment. It involved 99 adults with a specific type of lung cancer (adenocarcinoma) whose disease had progressed. The main goal was to see if the combination could shrink tumors and was safe for patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Christie NHS Hospital Foundation Trust
Manchester, M20 4BX, United Kingdom
-
Dartmouth-Hitchcock Medical Center (DHMC)
Lebanon, New Hampshire, 03756, United States
-
Guy's and St Thomas' NHS Foundation Trust
London, SE1 9RT, United Kingdom
-
Hospital Clinic Barcelona
Barcelona, 08036, Spain
-
Hospital Teresa Herrera
A Coruña, 15006, Spain
-
Hospital Universitari Germans Trias i Pujol-ICO
Barcelona, Badalona, 08916, Spain
-
Hospital Universitario 12 de Octubre, Servicio de oncologia
Madrid, 28041, Spain
-
Hospital Universitario Fundacion Jimene Diaz
Madrid, 28040, Spain
-
Hospital Universitario Vall d'Hebron (VHIR)
Barcelona, 08035, Spain
-
Hospital Universitario Virgen de la Victoria
Málaga, 29010, Spain
-
Medical College of Wisconsin, 9200 W Wisconsin Avenue
Milwaukee, Wisconsin, 53226-3522, United States
-
Radiumhospitalet, Oslo University Hospital PB
Oslo, 0424, Norway
-
Servicio de Oncologia Hospital del Mar
Barcelona, 08003, Spain
Conditions
Explore the condition pages connected to this study.